Emcure Pharma IPO opens for subscription on July 3, 2024 and closes on July 5, 2024. The allotment for the Emcure Pharma IPO is expected to be finalized on Monday, July 8, 2024. IPO will list on BSE, NSE with tentative listing date fixed as Wednesday, July 10, 2024. Emcure Pharma IPO is a book built issue of Rs 1,952.03 crores. The issue is a combination of fresh issue of 0.79 crore shares aggregating to Rs 800 crores and offer for sale of 1.14 crore shares aggregating to Rs 1,152.03 crores.


  • Issue Opens: Wednesday, July 03, 2024
  • Issue Closes: Friday, July 05, 2024
  • Face Value: Rs 10 each
  • Price Band: Rs 960 – 1008 per share
  • Lot Size: 14 Shares
  • Listing On: BSE & NSE
  • Basis of Allotment: July 8, 2024
  • Initiation of Refund: July 9, 2024
  • Credit to Demat: July 9, 2024
  • Listing Date: July 10, 2024

IPO price band is set at Rs 960 to Rs 1008 per share. The minimum lot size for an application is 14 Shares. The minimum amount of investment required by retail investors is Rs 14,112. The minimum lot size investment for NII is 15 lots (210 shares), amounting to Rs 211,680, and for NII, it is 71 lots (994 shares), amounting to Rs 1,001,952. Bids can be made for a minimum of 14 Equity Shares and in multiples of 14 Equity Shares thereafter. The Company proposes to utilize the net proceeds towards repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the Company and general corporate purposes. The Equity Shares are proposed to be listed on both BSE and the NSE.

Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas. The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023.

Financials

In the six months ended September 30, 2023, and the Financial Year 2023, sales contributed 50.84% and 53.16% of the company’s total revenue, respectively. The company’s Domestic sales grew at a CAGR of 10.80% between September 2019 and September 2023, outperforming the Indian pharmaceutical market. As of September 30, 2023, Emcure Pharma employed 552 scientists and operated five research facilities. They filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. They had 201 granted patents, 33 pending patent applications, and submitted 102 drug master files. Emcure Pharmaceuticals has 13 manufacturing facilities in India. These facilities can produce various pharmaceutical and biopharmaceutical products, including pills, liquids, injectables, and complex ingredients such as chiral molecules, iron molecules, and cytotoxic substances.

About the author: IE&M Team
IE&M Team
Indian Economy & Market is an Indian media and information platform producing data-backed news and analysis on all the vital elements at the intersection of the economy, stock markets, mutual fund, insurance, commodities, currency, technology, startups and business.

More articles by the author

Table of Contents